Faeth Therapeutics, Inc. (FTH) Stock Score, Valuation & Financial Research

Faeth Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for FTH

Faeth Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 29.74. These figures are a research snapshot, not a buy or sell recommendation.

What Faeth Therapeutics, Inc. does

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company that generates no commercial revenue. Its business model relies on raising capital through equity offerings and strategic financing to fund the research and development of proprietary multi-node therapies targeting tumor metabolism and signaling pathways.

Products and services

  • The company is developing PIKTOR, an investigational all-oral combination therapy of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway in cancer patients.

Brands and product families

  • PIKTOR — Lead investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party contract research organizations to conduct clinical trials and preclinical studies. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of drug candidates for clinical use. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various biopharmaceutical companies developing therapies for cancer and oncogenic pathway inhibition. Source

Business strengths to evaluate

  • Proprietary multi-node inhibition platform Source

Business risks and research considerations

  • History of operating losses and lack of commercial revenue Source
  • Dependence on clinical trial success and regulatory approval Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

FTH financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 29.74
Market capitalization:
766.66M (currency not supplied)
Revenue:
USD -4.85M
Net income:
USD -195.53M
Free cash flow:
USD -20.47M
Cash:
USD 26.9M
Total debt:
USD 592K
EPS:
USD -141.65

What stands out

  • Free cash flow is USD -20.47M, negative for the stored period.
  • The balance sheet shows USD 26.9M of cash versus USD 592K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 26.31M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for FTH

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can FTH fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is FTH likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for FTH to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of FTH's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research FTH

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.